217 related articles for article (PubMed ID: 16869455)
21. HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy.
Kirac D; Bayam E; Dagdelen M; Gezmis H; Sarikaya S; Pala S; Altunok EC; Genc E
Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):43-48. PubMed ID: 29096742
[TBL] [Abstract][Full Text] [Related]
22. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
[TBL] [Abstract][Full Text] [Related]
23. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
24. [Effects of polymorphism of apolipoprotein E gene on body mass index and plasma lipid levels in obese children].
Zhang X; Xia G; Mai G
Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Nov; 35(6):412-4. PubMed ID: 11840773
[TBL] [Abstract][Full Text] [Related]
25. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis.
de Maat MP; Jukema JW; Ye S; Zwinderman AH; Moghaddam PH; Beekman M; Kastelein JJ; van Boven AJ; Bruschke AV; Humphries SE; Kluft C; Henney AM
Am J Cardiol; 1999 Mar; 83(6):852-6. PubMed ID: 10190398
[TBL] [Abstract][Full Text] [Related]
26. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ; Zerba KE; Huang SP; Tsuchihashi Z; Kirchgessner T; Belder R; Vishnupad P; Hu B; Klerkx AH; Zwinderman AH; Jukema JW; Sacks FM; Kastelein JJ; Kuivenhoven JA
J Am Coll Cardiol; 2004 Mar; 43(5):854-7. PubMed ID: 14998629
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic study of statin therapy and cholesterol reduction.
Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
[TBL] [Abstract][Full Text] [Related]
28. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
Kuivenhoven JA; Jukema JW; Zwinderman AH; de Knijff P; McPherson R; Bruschke AV; Lie KI; Kastelein JJ
N Engl J Med; 1998 Jan; 338(2):86-93. PubMed ID: 9420339
[TBL] [Abstract][Full Text] [Related]
29. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
30. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW;
Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999
[TBL] [Abstract][Full Text] [Related]
31. Association of apolipoprotein E (ApoE) polymorphisms with risk of primary hyperuricemia in Uygur men, Xinjiang, China.
Sun YP; Zhang B; Miao L; Wang XM; Yu JH; Luo L; Ying L; Xin G; Haliakpaer G; Xia H; Yao H
Lipids Health Dis; 2015 Apr; 14():25. PubMed ID: 25890021
[TBL] [Abstract][Full Text] [Related]
32. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients.
Liberopoulos EN; Miltiadous GA; Cariolou M; Tselepis AD; Siamopoulos KC; Elisaf MS
Am J Kidney Dis; 2004 Aug; 44(2):300-8. PubMed ID: 15264189
[TBL] [Abstract][Full Text] [Related]
33. Statins improve visual field alterations related to hypercholesterolemia.
Alcalá A; Jansen S; Téllez T; Gómez-Huelgas R; Pérez O; Egido J; Farkouh ME
Atherosclerosis; 2010 Apr; 209(2):510-4. PubMed ID: 19892351
[TBL] [Abstract][Full Text] [Related]
34. Relationship between severity of coronary artery disease and apolipoprotein E gene polymorphism.
Arslan Ince FD; Atay A; Köseoğlu M; Yeşil M; Deveci E
Anadolu Kardiyol Derg; 2010 Jun; 10(3):202-8. PubMed ID: 20538553
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy.
Ballantyne CM; Herd JA; Stein EA; Ferlic LL; Dunn JK; Gotto AM; Marian AJ
J Am Coll Cardiol; 2000 Nov; 36(5):1572-8. PubMed ID: 11079660
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Voora D; Shah SH; Reed CR; Zhai J; Crosslin DR; Messer C; Salisbury BA; Ginsburg GS
Circ Cardiovasc Genet; 2008 Dec; 1(2):100-6. PubMed ID: 20031551
[TBL] [Abstract][Full Text] [Related]
37. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.
Peña R; Lahoz C; Mostaza JM; Jiménez J; Subirats E; Pintó X; Taboada M; López-Pastor A;
J Intern Med; 2002 Jun; 251(6):518-25. PubMed ID: 12028507
[TBL] [Abstract][Full Text] [Related]
38. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
Ordovas JM; Lopez-Miranda J; Perez-Jimenez F; Rodriguez C; Park JS; Cole T; Schaefer EJ
Atherosclerosis; 1995 Mar; 113(2):157-66. PubMed ID: 7605354
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study.
Mendes-Lana A; Pena GG; Freitas SN; Lima AA; Nicolato RL; Nascimento-Neto RM; Machado-Coelho GL; Freitas RN
Braz J Med Biol Res; 2007 Jan; 40(1):49-56. PubMed ID: 17224996
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease.
Muendlein A; Saely CH; Marte T; Schmid F; Koch L; Rein P; Langer P; Aczel S; Drexel H
Atherosclerosis; 2008 Jul; 199(1):179-86. PubMed ID: 18289550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
